- Home
- MNSB vs ALDX Comparison
MNSB vs ALDX Comparison
Compare MNSB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- ALDX
- Stock Information
- Founded
- MNSB 2003
- ALDX 2004
- Country
- MNSB United States
- ALDX United States
- Employees
- MNSB N/A
- ALDX N/A
- Industry
- MNSB Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- ALDX Health Care
- Exchange
- MNSB Nasdaq
- ALDX Nasdaq
- Market Cap
- MNSB 140.7M
- ALDX 160.8M
- IPO Year
- MNSB N/A
- ALDX 2014
- Fundamental
- Price
- MNSB $18.30
- ALDX $3.05
- Analyst Decision
- MNSB
- ALDX Strong Buy
- Analyst Count
- MNSB 0
- ALDX 2
- Target Price
- MNSB N/A
- ALDX $9.50
- AVG Volume (30 Days)
- MNSB 23.4K
- ALDX 769.8K
- Earning Date
- MNSB 07-28-2025
- ALDX 07-31-2025
- Dividend Yield
- MNSB 2.17%
- ALDX N/A
- EPS Growth
- MNSB N/A
- ALDX N/A
- EPS
- MNSB N/A
- ALDX N/A
- Revenue
- MNSB $59,896,000.00
- ALDX N/A
- Revenue This Year
- MNSB $17.95
- ALDX N/A
- Revenue Next Year
- MNSB $2.52
- ALDX N/A
- P/E Ratio
- MNSB N/A
- ALDX N/A
- Revenue Growth
- MNSB N/A
- ALDX N/A
- 52 Week Low
- MNSB $15.00
- ALDX $1.14
- 52 Week High
- MNSB $20.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- MNSB 45.27
- ALDX 61.89
- Support Level
- MNSB $18.00
- ALDX $2.60
- Resistance Level
- MNSB $18.52
- ALDX $3.24
- Average True Range (ATR)
- MNSB 0.46
- ALDX 0.22
- MACD
- MNSB -0.07
- ALDX 0.09
- Stochastic Oscillator
- MNSB 24.65
- ALDX 80.93
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.